Mostrando 10 resultados de: 12
Filtros aplicados
Publisher
Journal of Nanobiotechnology(2)
Molecular Neurobiology(2)
Applied Sciences (Switzerland)(1)
Cell and Bioscience(1)
Current Pharmaceutical Design(1)
Área temáticas
Enfermedades(12)
Fisiología humana(6)
Medicina y salud(6)
Farmacología y terapéutica(5)
Ginecología, obstetricia, pediatría, geriatría(2)
Área de conocimiento
Neurología(6)
Neuropsicología(4)
Farmacología(3)
Medicamento(2)
Biología molecular(1)
Origen
scopus(12)
A chronological review of potential disease-modifying therapeutic strategies for Alzheimer's disease
ReviewAbstract: Late-onset Alzheimer’s disease (LOAD) is a neurodegenerative disorder that has become a worldwide hePalabras claves:Alzheimer’s disease, calcium, ER stress, glutamate, Neurodegeneration, neuroinflammation, Oxidative Stress, Parkinson’s DiseaseAutores:Antoni Camins, Auladell C., Busquets O., Espinosa-Jimenez T., Ettcheto M., Verdaguer E.Fuentes:scopusA novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet
ArticleAbstract: Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the globaPalabras claves:Alzheimer’s disease, BACE1, BDNF, cognitive decline, dendritic spines, high-fat diet, neuroinflammation, Rhein-huprine hybrid, Tau, TLR4Autores:Antoni Camins, Auladell C., Bulló M., Cano A., Espinosa-Jimenez T., Ettcheto M., Folch J., Muñoz-Torrero D., Olloquequi J., Parcerisas A., Pont C., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusExtracellular vesicles, the emerging mirrors of brain physiopathology
ArticleAbstract: Extracellular vesicles are secreted by a wide variety of cells, and their primary functions includePalabras claves:Alzheimer’s disease, exosomes, Extracellular vesicles, Glioblastoma, multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative diseases, Parkinson’s DiseaseAutores:Antoni Camins, Bernuz M., Boada M., Cano A., de Antonio E.E., Ettcheto M., Martí M., Pividori M.I., Puerta R., Ruíz A., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusEvaluation of the Role of JNK1 in the Hippocampus in an Experimental Model of Familial Alzheimer’s Disease
ArticleAbstract: c-Jun N-terminal kinases (JNKs), which belong to a mitogen-activated protein kinase (MAPK) family, aPalabras claves:Alzheimer’s disease, amyloid, Amyloid precursor protein, APPswe/PS1dE9, BACE1, JNK1, PGC-1α, Transgenic mouse models, β-secretase, βAAutores:Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., Luque M., Pallás M., Pedros I., Petrov D., Verdaguer E.Fuentes:scopusNanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer’s disease: from current to future challenges
ReviewAbstract: Increasing life expectancy has led to an aging population, which has consequently increased the prevPalabras claves:Alzheimer’s disease, Biomarkers, lipid nanoparticles, Metal nanoparticles, nanotechnology, Polymeric nanoparticlesAutores:Antoni Camins, Boada M., Cano A., Duskey J.T., Ettcheto M., García M.L., Marquié M., Ruiz A., Sanchez-Lopez E., Souto E.M.B., Tosi G., Turowski P.Fuentes:scopusMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment
ReviewAbstract: Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effPalabras claves:Alzheimer’s disease, AMP activated protein kinase AMPK, Beta amyloid, diabetes mellitus, Insulin Resistance, Metformin, Tau protein hyperphosphorylationAutores:Antoni Camins, Cano A., Ettcheto M., Javan M., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E.Fuentes:scopusPeripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer’s Disease
ArticleAbstract: There is growing evidence that obesity associated with type 2 diabetes mellitus (T2DM) and aging arePalabras claves:Alzheimer’s disease, APPswe/PS1dE9, DIABÉTES, high-fat diet, Memantine, obesityAutores:Antoni Camins, Auladell C., Busquets O., Cabrera H., Carro E., Casadesús G., Ettcheto M., Folch J., García M.L., Gómez-Mínguez Y., Sanchez-Lopez E., Vázquez-Carrera M., Zárate C.B.Fuentes:scopusTriple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease
ArticleAbstract:Palabras claves:Alzheimer’s disease, glucagon, glucagon-like peptide, glucose-dependent insulinotropic peptide, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Castro-Torres R.D., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sureda F.X., Verdaguer E., Zárate C.B.Fuentes:scopusPlasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment
ArticleAbstract: In the clinical course of Alzheimer’s disease (AD) development, the dementia phase is commonly precePalabras claves:Alzheimer’s disease, Cerebrospinal fluid, Extracellular vesicles, Mild cognitive impairment, Plasma exosomes, proteomicsAutores:Alarcón-Martín E., Alegret M., Antoni Camins, Bernuz M., Boada M., Cano A., de Rojas I., Esteban-de-Antonio E., Ettcheto M., García-González P., Gomez-Chiari M., Marquié M., Martí M., Martín E., Martino-Adami P.V., Montrreal L., Núñez-Llaves R., Olivé C., Orellana A., Pérez-Cordón A., Pividori M.I., Puerta R., Ramírez A., Ruiz A., Sotolongo-Grau Ó., Tárraga L., Tejero M.Á., Valero S., Vivas A.Fuentes:scopusPolymeric nanoparticles as drug delivery systems for dementia
Book PartAbstract: Dementia affects around 50 million people worldwide and it is one of the main causes of disability aPalabras claves:Alzheimer’s disease, dementia, drug delivery, Nanomedicine, PLGA, Polymeric nanoparticlesAutores:Antoni Camins, Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopus